



DOI: 10.32768/abc.2024113262-268



Association Between Smoking and a Molecular Profile of Breast Cancer

Greetchen Borges de Campos Bólico Ferreira^a, Ildo Borges de Campos Bolico Ferreira^b, Jamile Ahmed Borges Geha^c, Maria Cecília Leite de Moraes^{a,d}, Luciano Amorim Meirelles^e, Elias Ferreira Porto^a

^aAdventist University of São Paulo, Sao Paulo, Brazil

^bFaculty of Engineering of Guaratinguetá, Universidade Estadual Paulista “Júlio de Mesquita Filho”, Guaratinguetá, Brazil

^cFaculty of Dentistry and Dental Research Center São Leopoldo Mandic, Sao Paulo, Brazil

^dFaculty of Public Health of the University of São Paulo, Sao Paulo, Brazil/ Pontifical Catholic University of Campinas, Sao Paulo, Brazil

^eUNASP, Adventist University of São Paulo, Sao Paulo, Brazil

ARTICLE INFO

Received:
23 April 2024
Revised:
9 July 2024
Accepted:
10 July 2024

Keywords:
breast cancer, smoking,
mortality, survival

ABSTRACT

Background: Female breast cancer is one of the causes of the highest cancer mortality and morbidity in the world. It is already known that there is a strong association between smoking and breast cancer. However, the association between smoking and tumor severity is not very clear. The objective of this study was to assess the severity of the breast tumor, using the tumor's molecular classification as a tool according to its immunohistochemical profile in smoking and nonsmoking women.

Methods: This is a longitudinal study in which 208 women with a diagnosis of breast cancer were followed for 17 months, 80 of whom were smokers, and all underwent anatomopathological diagnosis by core biopsy and subsequent immunohistochemistry, followed by treatment indicated according to the type and the clinical staging of the tumor. The severity of the tumor was assessed by its molecular classification according to its immunohistochemical profile.

Results: Smoking was associated with higher mortality. The tumor with the most severe immunohistochemical profile was found in younger smokers. Overall, 19.7% of smokers and 10% of non-smokers had a triple-negative tumor. The age of female smokers with triple negative was 48.2 years, and that of nonsmoking women was 52.6 years ($P=0.005$). In 17 months of follow-up, mortality among smokers was 39.5% and for nonsmokers, 20%. Survival was statistically significantly lower among the group of smokers ($P=0.01$).

Conclusion: Smoking is associated with greater breast cancer severity, as the risk for cancer severity was 5.5 times higher for the smoking group, and survival was statistically significantly lower among the smoking group.

Copyright © 2024. This is an open-access article distributed under the terms of the [Creative Commons Attribution-Non-Commercial 4.0](https://creativecommons.org/licenses/by-nc/4.0/) International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.

INTRODUCTION

Breast cancer is one of the causes of the highest cancer mortality and morbidity in the world.¹ It is more prevalent in women, being the major cause of cancer death among them. The profile of women's lifestyle has changed in recent years amid the social transformation occurring in these decades, as well as

*Address for correspondence:

Elias Ferreira Porto,
Professor, Estrada de Itapeverica da Serra 5859 – São
Paulo – SP – Brazil - Zip code – 05858001
Tel: +5511992223620
Email: eliasporto@gmail.com; elias.porto@unasp.edu.br



Sentinel lymph node (SLN) biopsy is a standard procedure for patients with clinically node-negative (cN0) breast cancer, playing a crucial role in determining the need for axillary lymph node dissection (ALND). ALND is unnecessary not only in patients with negative SLNs^{1,2}, but also in those with one or two positive SLNs undergoing breast- the prevalence of diseases that affect women. In this context, the new lifestyle adopted by today's women, including smoking, explains part of the emergence of certain diseases.^{2,3} For Brazil, according to the National Cancer Institute¹, which is the national reference government agency for the treatment of this disease, 59,700 new cases of breast cancer are expected, with an estimated risk of 5.6, 33 cases per 100,000 women.

Breast cancer is a chronic disease characterized by disordered cell growth, resulting from genetic mutations. It is estimated that 90–95% of them are sporadic (non-familial) and result from somatic mutations, damage to genetic material that accumulates throughout life. It is also estimated that 5–10% are hereditary (family members) due to the inheritance of a germline mutation at birth, which gives these women a greater susceptibility to breast cancer during their lifetime.^{4,5} The modern western model of life produces and reproduces risk factors that directly influence carcinogenesis.⁶

Some studies have shown that the carcinogenic agents present in tobacco, for example, are polycyclic aromatic hydrocarbons, aromatic amines, and N-nitrosamines.^{3,5,7} They can be transported through the bloodstream to the mammary glandular tissue, initiating the neoplastic process by damaging the nuclear DNA content with these agents.⁸ However, it is not entirely clear whether these lesions in the cell DNA caused by these agents make the tumor more aggressive.

A study published in the scientific journal *Cancer*, from the American Cancer Society, reported the link between tobacco consumption and the most

common type of breast cancer in young women. In the study, researchers concluded that patients under 44 years of age who smoke at least 1 pack of cigarettes a day for at least ten years have a 60% higher risk of developing tumors, but it is not yet known whether tobacco is related to the severity of the disease.⁹

Given this, the objective of this study is to compare the severity of breast cancer according to the molecular classification.^{3,4} According to its immunohistochemical profile (luminal A, luminal B, hybrid luminal, *HER2* overexpression, and triple negative),^{5,6} clinical staging (early encompassing stages from 0 to IIB, and late encompassing stages from III to IV) and survival, among a group of smoking and nonsmoking women.

METHODS

This is a longitudinal study with a quantitative approach, involving 208 women with breast carcinoma undergoing treatment at the mastology service of 2 public hospitals in the State of São Paulo. Among them, 80 were smokers and 128 were non-smokers. These were all breast cancer patients treated during the study period. Smokers were considered those who regularly used at least one cigarette per day.

Follow-up was carried out by visits every 15 days during the chemotherapy period, and every 30 days after this period. After 17 months, data from these consultations were not included in this study.

This study included women aged 25 to 65 years who, at the time of breast cancer diagnosis, had a history of full-term pregnancy (38 to 41 weeks of gestational age) with breastfeeding exercise of at least one month.

The study did not include women with other types of previous cancer, men with breast cancer, or any other condition of autoimmune diseases or immune deficiency (Figure 1).




Figure 1. Patient Randomization Flowchart



The diagnosis of breast cancer was made using pathological and immunohistochemical exams.^{10,11} Smokers were those who smoked at least one cigarette per day.

The sample was of a convenience nature, from patients who sought the Unified Health System (SUS) service, scheduled at random by the “State Regulation System” (SISREG), for the specialty of mastology. The concomitance of the diagnosis of breast cancer and the pregnant puerperal period was considered positive if the diagnosis of breast cancer occurred during pregnancy or in the year after delivery. This protocol was approved by the institutional ethics committee under number 1,064,564. All patients signed a free and informed consent form.

The molecular classification^{3,4} of the tumor followed pre-established criteria that define distinct subtypes according to the molecular studies of breast carcinoma based on the identification of the gene expression profile using the microarray cDNA.¹² The subtypes were: Luminal A, Luminal B, Luminal Hybrid, *HER2* overexpression, and triple-negative. The clinical staging of the tumors followed the criteria defined by the tumor, node, metastasis (TNM)¹⁴ system of the International Union against Cancer.

The immunohistochemical diagnosis was performed by histological sections, with the respective positive and negative controls undergoing immunohistochemical examination in an automated

system with antigen recovery in PTLINK (Dako) and incubation, development, and counterstaining in AutoStainer Link, using highly sensitive polymer and ready-to-use FLEX antibodies. The calculation of mortality was established from the moment of diagnosis until 17 months after.^{12,13}

The statistical analysis was based on the Kolmogorov-Smirnov normality test to assess the distribution of data in relation to normality. Data were presented as means and standard deviations; the odds ratio test was used for categorical variables of severe or non-severe cancer (smoker vs non-smoker) between the groups. The variables related to the results of exams were evaluated by means of analysis of variance. Survival between smokers and non-smokers was analyzed using the Kaplan-Meier test. $P < 0.05$ was considered statistically significant.

RESULTS

Of 208 women with breast cancer undergoing treatment, 30 were excluded. Overall, 80 women reported smoking and 128 were classified as non-smokers. No difference was found between the smoking and nonsmoking groups in the anthropometric data and age at diagnosis; however, in the nonsmoking group, there was a higher proportion of women with arterial hypertension, as shown in Table 1.

Table 1. Distribution of patients with breast cancer according to smoking

Variables	Smoking n=80	Nonsmoking n=128	P
	mean±SD	mean±SD	
Age, y	52.4±7.3	54.5±8.1	0.85
BMI, kg/m ²	28.1±4.7	29.4±4.9	0.67
Number of children	2.5±1.4	2.5±1.5	0.99
Age of diagnosis, y	51.3±8.6	53.2±8.4	0.61
Age of first pregnancy, y	23.5±5.7	24.7±6.6	0.58
	%	%	P
Family history	25.3	14.8	0.04
Arterial hypertension	59.0	74.2	0.02
Diabetes	23.0	22.6	0.86

Chi-square test

In general, the molecular profile and gene expression of cancer most frequently found was Luminal B, followed by Luminal A, triple negative, Luminal Hybrid, and *HER2* overexpression. However, it was seen that for the group of nonsmoking women, there was a higher proportion of

women with Luminal A and B types, while among smokers, there was a higher proportion of women with Luminal B, Luminal A, and triple-negative tumors, according to Table 2.

For the sample studied, the clinical stage most frequently found was I, followed by IIB, IIA, and IIIA



at the same frequency, IIIB, and IV. No difference was found for the groups in relation to clinical staging, as shown in Table 3.

Table 2. Distribution of the Molecular Profile and Gene Expression of the Tumor in Patients with Associated Breast Cancer and Smoking

Variables (Molecular Profile)	Smoker n=80	Nonsmoker n=128	P
Luminal A, %	24.0	35.9	0.035
Luminal B, %	31.3	35.9	0.246
Luminal hybrid, %	14.4	11.7	0.281
HER2 overexpression, %	7.2	6.3	0.391
Triple-negative, %	19.0	10.1	0.030
Others, %	4.1	0.1	0.85
Total, %	100	100	-

Chi-square test

Figure 3 presents the results of the comparative analysis of the risk for the severity of cancer (neoadjuvant chemotherapy groups) for the smoking and nonsmoking groups. The analysis showed that the risk of more severe cancer is 5.5 times higher for smokers compared to the group of nonsmoking patients.

Table 3. Distribution of the Clinical Stage of the Tumor in Patients with Associated Breast Cancer and Smoking

Variables (clinical stage)	Smokers n=80	Nonsmokers n=128	P
I, %	36.1	35.9	0.45
IIA, %	15.6	25.0	0.09
IIB, %	19.2	15.6	0.12
IIIA, %	14.4	13.2	0.85
IIIB, %	13.2	10.3	0.45
IV, %	1.5	0.5	0.84
Total	100	100	

Chi-square test




Figure 4 shows the results of the assessment of survival among patients with breast cancer, smokers, and nonsmokers, during a 17-month follow-up period. It was seen that the survival of the nonsmoking group was significantly higher than that

of the smoking group ($P=0.01$). On average, the survival of nonsmoking patients was 240 days. It was also found that the risk of death for these patients was 2.2 (95% CI, 1.19–4.58).




Figure 3. Risk of Severe Cancer in the 2 Groups




Figure 4. Survival of the 2 Groups in 510 Days of Follow-Up

DISCUSSION

The main objective of this study was to assess whether smoking is related to the severity of breast cancer. Among the most important results demonstrated are the association between smoking and the histological severity of cancer, and that smoking anticipates the appearance of breast cancer by at least 3 years.

It has been seen that younger patients and smokers have histologically more severe breast cancer. Young patients, under the age of 35, have a higher incidence of high histological grade tumors (undifferentiated cells), high cell proliferation with a high mitotic index, marked cell pleomorphism, high cytoplasm-to-nucleus ratio, and higher proportions of tumors with negative estrogen receptors and/or overexpression of *HER2*.¹⁴

The 2013 PLATINO Study¹⁵ showed that there are approximately 14% of adult smokers in Brazil. The profile of women with breast cancer studied showed a high number of cases associated with tobacco use between the two groups.

In this study,¹⁶ the prevalence of the most serious type of cancer, i.e., triple negative, was almost double in smokers compared to nonsmokers, and was also associated with younger women. In a case-control study, it was found that younger age at smoking initiation is related to younger age at diagnosis. Smokers were diagnosed on average 10 years earlier than non-smokers, and the incidence of the invasive carcinoma subtype increased with the intensity and

duration of smoking. Di Cello *et al.*¹⁴ suggested that cigarette smoke promotes epithelial-to-mesenchymal transition, producing a more aggressive breast cancer phenotype in vitro.

In a study of 73,388 women, of whom 3721 patients had invasive breast cancer identified during an average follow-up of 13.8 years, the incidence was higher among current smokers and ex-smokers (hazard ratio [HR]=1.13) than those who never smoked. It was also seen that women who started smoking before menarche (HR=1.61) or before the first pregnancy (HR=1.45) were at higher risk.¹⁷ In this study, mortality was higher among female smokers. This was possibly due to the molecular changes caused by smoking, which enable the development of more invasive tumors with a greater probability of manifestation in other organs. The risk of progression and death from oropharyngeal cancer increases directly as a result of exposure to tobacco at the time of diagnosis and during therapy and is independent of tumor status and treatment.¹⁸

Tobacco is one of the risk factors for the development of cancer of the respiratory and non-respiratory pathways through carcinogens in its composition, such as polycyclic aromatic hydrocarbons, aromatic amines, and N-nitrosamines.^{3,5,7} Tobacco carcinogens cross the alveolar membrane and go into the bloodstream, where they are transported to the breast tissue via plasma lipoproteins. These carcinogenic agents can be stored in the fatty tissue of the mammary gland and metabolized and activated by the epithelial cells of the breast.^{18,19}

According to the prospective Women's Health Initiative Observational study, conducted by the Health Partners Research Foundation, Minneapolis, USA, from 1993 to 1998 to determine links between smoking and breast cancer, where 80,000 women were analyzed and followed for 10 years, 3250 cases of invasive breast cancer were identified. The results showed that women who smoke after menopause are 16% more likely to develop breast cancer than women who have never smoked in their lives, and ex-smokers have a 9% chance. There is a greater danger among those who smoke after 50 years of age, or those who start smoking in adolescence, periods considered to be a "risk window" for breast cancer. The risk of developing cancer persists until twenty years after the woman stops smoking.^{20,21}

Therefore, the relationship between histologically more severe breast cancer in younger patients and smoking has distinct biological characteristics for worse prognosis and shorter survival. Very consistent data, such as the California Teachers Study,²² where more than 116,000 women



were followed for 5 years, confirm the importance of smoking in the risk of breast cancer, stressing that women with no family history of the disease have a higher risk of cancer when they are smokers. Other studies show that smoking is an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer.⁷

The limitations of this study include the fact that the follow-up was not carried out until 5 years, which could have better shown the outcome of all women. However, this study has important clinical implications. The main implication that makes this study unique is that smoking is related to the severity of the disease. This information is important in terms of health promotion in encouraging women to avoid smoking, and also to relate the prevalence based on the number of women who smoke.

CONCLUSION

This study showed an association between smoking and breast cancer, with a more severe molecular profile for women who smoke, and a strong relationship was also seen between early smoking initiation and higher mortality. The molecular subtype with triple negative gene

expression had a frequency of 19.0% in women who smoked and only 10.1% in women who did not smoke. The mean age of triple-negative smoking women was 48.2 years, and the age of nonsmoking women was 52.6 ($P=0.005$). In 17 months of follow-up, mortality among smokers and among non-smokers was 39.5% and 20%, respectively.

ETHICAL CONSIDERATIONS

This protocol was approved by the institutional ethics committee under number 1,064,564. All patients signed a free and informed consent form.

FUNDING

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST

The authors have no relevant financial or nonfinancial interests to disclose.

ACKNOWLEDGMENTS

None.

REFERENCES

- ten Broeke SW, Suerink M, Nielsen M. Response to Roberts *et al.* 2018: is breast cancer truly caused by MSH6 and PMS2 variants or is it simply due to a high prevalence of these variants in the population? *Genet Med.* janeiro de 2019;21(1):256–7.
- Mm G, Sm G, J S, Wr D, Lm H, Mj T. Active smoking and breast cancer risk: original cohort data and meta-analysis. *J Natl Cancer Inst* [Internet]. 17 de abril de 2013 [citado 2 de julho de 2024];105(8). Disponível em: <https://pubmed.ncbi.nlm.nih.gov/23449445/>
- Gram IT, Park SY, Kolonel LN, Maskarinec G, Wilkens LR, Henderson BE, *et al.* Smoking and Risk of Breast Cancer in a Racially/Ethnically Diverse Population of Mainly Women Who Do Not Drink Alcohol. *Am J Epidemiol.* 1o de dezembro de 2015;182(11):917–25.
- Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, *et al.* Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *J Natl Cancer Inst.* 20 de maio de 2009;101(10):736–50.
- HMX | Harvard Medical School [Internet]. [citado 2 de julho de 2024]. HMX Pro Genetics - Cancer Genomics and Precision Oncology - Harvard Medical School. Disponível em: <https://onlinelearning.hms.harvard.edu/hmx/courses/cancer-genomics/>
- Duda-Szymańska J, Sporny S. [The practical value of breast cancer molecular classification]. *Pol Merkurius Lek.* julho de 2011;31(181):5–8.
- Scientific TF. Next-Generation Sequencing for Pathologists [Internet]. [citado 2 de julho de 2024]. Disponível em: <https://www.oncomine.com/ngs-for-pathologists>
- A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. - Abstract - Europe PMC [Internet]. [citado 9 de julho de 2024]. Disponível em: <https://europepmc.org/article/pmc/6080768>
- He Y, Li X, Si Y, Hong J, Yu C, Gu L. The relationship between tobacco and breast cancer incidence: A systematic review and meta-analysis of observational studies. *Front Oncol* [Internet]. 15 de setembro de 2022 [citado 9 de julho de 2024];12. Disponível em: <https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.961970/full>
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer | Journal of Clinical Oncology [Internet]. [citado 9 de julho de 2024]. Disponível em: <https://ascopubs.org/doi/full/10.1200/JCO.2009.25.6529>
- Prajapati S, Martinez C, Bahadur A, Wu I, Zheng W, Lechleiter J, *et al.* Near-Infrared Imaging of Injured Tissue in Living Subjects Using IR-820. *Mol Imaging.* 1o de janeiro de 2009;8:45–54.



12. Darb-Esfahani S, von Minckwitz G, Denkert C, Ataseven B, Högel B, Mehta K, *et al.* Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. *BMC Cancer*. 28 de julho de 2014;14:546.
13. Desrichard A, Bidet Y, Uhrhammer N, Bignon YJ. CHEK2 contribution to hereditary breast cancer in non-BRCA families. *Breast Cancer Res BCR*. 2011;13(6):R119.
14. Di Cello F, Flowers VL, Li H, Vecchio-Pagán B, Gordon B, Harbom K, *et al.* Cigarette smoke induces epithelial to mesenchymal transition and increases the metastatic ability of breast cancer cells. *Mol Cancer*. 6 de agosto de 2013;12(1):90.
15. Menezes AMB, Jardim JR, Pérez-Padilla R, Camelier A, Rosa F, Nascimento O, *et al.* Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in São Paulo, Brazil. *Cad Saúde Pública*. outubro de 2005;21:1565–73.
16. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast cancer risk: original cohort data and meta-analysis. *J Natl Cancer Inst*. 17 de abril de 2013;105(8):515–25.
17. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients [Internet]. [citado 9 de julho de 2024]. Disponível em: <http://ouci.dnfb.gov.ua/en/works/leW8dOO7/>
18. Gillison ML, Zhang Q, Jordan R, Xiao W, Westra WH, Trotti A, *et al.* Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. 10 de junho de 2012;30(17):2102–11.
19. Read “Premium Cigars: Patterns of Use, Marketing, and Health Effects” at NAP.edu [Internet]. [citado 9 de julho de 2024]. Disponível em: <https://nap.nationalacademies.org/read/26421/chapter/9>
20. Articles | Medical Oncology [Internet]. [citado 3 de julho de 2024]. Disponível em: <https://link.springer.com/journal/12032/articles?page=26>
21. Kenfield SA, Stampfer MJ, Rosner BA, Colditz GA. Smoking and Smoking Cessation in Relation to Mortality. *JAMA J Am Med Assoc*. 7 de maio de 2008;299(17):2037–47.
22. Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D, *et al.* High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). *Cancer Causes Control CCC*. setembro de 2002;13(7):625–35.

How to Cite This Article

de Campos Bólico Ferreira GB, de Campos Bólico Ferreira Ferreira IB, Geha JAB, de Moraes MCL, Meirelles LA, Porto EF. Association Between Smoking and a Molecular Profile of Breast Cancer. *Arch Breast Cancer*. 2024; 11(3):262-8.

Available from: <https://www.archbreastcancer.com/index.php/abc/article/view/938>